Genmab Advances Rina S Into Phase 2 GI Cancer Trial, Raising Long Term Pipeline Hopes

Genmab (Otc) (GMAB) announced an update on their ongoing clinical study.

Genmab (OTC: GMAB) has launched a Phase 2 study called “A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers.” The trial aims to see how well Rina S works in hard to treat GI cancers and how safe it is, which could open a new growth path in a large oncology market.

The study tests Rina S, also called rinatabart sesutecan, an antibody based drug given by IV infusion. It is used alone, without chemotherapy or other cancer drugs, to see if single agent activity is strong enough to justify larger late stage trials in GI tumors.

This is an interventional Phase 2 study with about 160 patients placed into parallel groups that all receive active treatment. There is no placebo and no blinding, so doctors and patients know they are getting Rina S, and the main goal is to treat cancer and measure tumor response and safety over time.

The trial started recruiting in April 2026, marking the formal launch of this GI cancer program for Genmab. The primary completion and final completion dates are not yet posted, but the last update on May 4, 2026 confirms that the protocol and recruiting status remain current.

For investors, this update reinforces Genmab’s push to expand beyond its established antibody portfolio into new targeted cancer drugs. Early signs of benefit in GI tumors could support higher long term revenue expectations, improve sentiment around GMAB’s pipeline, and sharpen competition with oncology players such as Roche, AstraZeneca, and Daiichi Sankyo in the antibody drug conjugate space.

The Rina S Phase 2 study in advanced GI cancers is now recruiting and remains active, with more details and future updates available on the ClinicalTrials.gov portal.

To learn more about GMAB’s potential, visit the Genmab (Otc) drug pipeline page.